Top

World Journal of Surgery

Published in:

01-08-2020 | Hepatocellular Carcinoma | Original Scientific Report

Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy

Authors: T. Hamada, K. Yano, T. Wada, N. Imamura, M. Hiyoshi, K. Kondo, Atsushi Nanashima

Published in: World Journal of Surgery | Issue 8/2020

Abstract

Background

The role of adjuvant hepatic intra-arterial infusion chemotherapy (HAI) is considered to be a promising option.

Methods

We examined treatment effects of adjuvant HAI using cisplatin in 37 hepatocellular carcinoma (HCC) patients with portal vein infiltration (PVI) who underwent hepatectomy in comparison with those in 85 patients who did not.

Results

PVI in 89 patients. Increased levels of aspartate transaminase, tumor markers, size and microvessel tumor infiltration (MVI) or cirrhosis, poorly differentiation, non-adjuvant HAI was associated with lower overall survival (p = 0.09). Poor differentiation, MVI and HAI were independently risk factors associated with tumor-free and overall survivals by the multivariate analysis (p < 0.05). Adjuvant HAI tended to show longer survivals in comparison with no-HAI (p = 0.08) and the multivariate analysis revealed significant efficacy of HAI for better prognosis.

Conclusion

Adjuvant HAI showed effectiveness on prolonging tumor-free and patient survival in HCC with PVI and is a promising option in the daily clinical practice.

Bosch FX, Ribes J, Díaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–16CrossRef

Sartorius K, Sartorius B, Aldous C et al (2015) Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol 39:284–290CrossRef

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917CrossRef

Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373:614–616CrossRef

Tandon P, Garcia-Tsao G (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29:502–510CrossRef

Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRef

Tung-Ping Poon R, Fan ST et al (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef

Choi KK, Kim SH, Choi SB et al (2011) Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 26:1646–1651CrossRef

Fukuda S, Okuda K, Imamura M et al (2002) Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 131:300–310CrossRef

10.

Nitta H, Beppu T, Imai K et al (2013) Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg 37:1034–1042CrossRef

11.

Peng BG, He Q, Li JP, Zhou F (2009) Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198:313–318CrossRef

12.

Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928CrossRef

13.

Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469CrossRef

14.

Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRef

15.

Song DS, Bae SH, Song MJ et al (2013) Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 19:4679–4788CrossRef

16.

Ando E, Tanaka M, Yamashita F et al (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95:588–595CrossRef

17.

Lin CC, Hung CF, Chen WT, Lin SM (2015) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver Cancer 4:228–240CrossRef

18.

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRef

19.

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRef

20.

Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef

21.

Kondo K, Chijiiwa K, Kai M et al (2009) Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 13:1078–1083CrossRef

22.

Liver Cancer Study Group of Japan (2015) The general rules for the clinical and pathological study of primary liver cancer, 6th edn. Tokyo, Kanahara

23.

Huang SX, Wu YL, Tang CW et al (2015) Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma. Hepatogastroenterol 62:122–125

24.

Jiang JH, Guo Z, Lu HF et al (2015) Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol 21:4627–4634CrossRef

25.

Ueshima K, Kudo M, Tanaka M et al (2015) Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer 4:263–273CrossRef

26.

Ogasawara S, Chiba T, Ooka Y et al (2014) Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87:330–341CrossRef

27.

Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483CrossRef

28.

Lee HS, Choi GH, Choi JS et al (2014) Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. Ann Surg Oncol 21:3646–3453CrossRef

29.

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66CrossRef

30.

Forner A, Da Fonseca LG, Díaz-González Á et al (2019) (2019) Controversies in the management of hepatocellular carcinoma. JHEP Rep 1:17–29CrossRef

31.

Johnson BW, Wright GP (2019) Regional therapies for the treatment of primary and metastatic hepatic tumors: a disease-based review of techniques and critical appraisal of current evidence. Am J Surg 217:541–545CrossRef

Title: Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy
Authors: T. Hamada
K. Yano
T. Wada
N. Imamura
M. Hiyoshi
K. Kondo
Atsushi Nanashima
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Cytostatic Therapy
Published in: World Journal of Surgery / Issue 8/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-020-05527-w

At a glance: The STEP trials

Springer Medicine

Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2020

Letter to The Editor: COVID-19: Looking South and East in the World for Guidance

Does Obstructive Sleep Apnea Affect Perioperative Complications? A Retrospective Study Using a Modified NSQIP Database

Listening to Music to Improve Laparoscopic Learning Performance? Great but Which One?

Development, Growth, and Maturation of Pancreatoduodenectomy Program: Future Directions

The IAES-Supported Malaysian Breast and Endocrine Surgery Course: 7 Years of Successful Collaborative Teaching

The Decreasing Incidence of Acute Appendicitis During COVID-19: A Retrospective Multi-centre Study